Cheplapharm Arzneimittel GmbH
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cheplapharm Arzneimittel GmbH
The cholesterol lowerer Crestor, which had peak sales of over $6.60bn, helped AstraZeneca reinvigorate a flagging pipeline. Now it is deemed surplus to requirements.
Japanese major presses on with post-Shire divestments even after passing strategic target.
Continuing parent firm Gilead’s busy deal-making year in immuno-oncology, Kite gets option rights to new targets. Boehringer teams with Israel’s BiomX in IBD research.
Deal news from Strides Pharma, Pharmaceutics Intl., Cipla, Wanbury, AstraZeneca, Syntekabio, Arctoris, Mundipharma, Samsung Bioepis…
- Specialty Pharmaceuticals
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools